PCDHGB8P: A Promising PCDHG Subfamily B Molecule as a Drug Target and Biomarker

Target Name: PCDHGB8P

NCBI ID: G56120

PCDHGB8P

Other Name(s): Protocadherin gamma subfamily B, 8 pseudogene | protocadherin gamma subfamily B, 8 pseudogene | PCDH-PSI3

PCDHGB8P: A Promising PCDHG Subfamily B Molecule as a Drug Target and Biomarker

PCDHGs (Protocadherin genes) are a family of transmembrane proteins that regulate cell-cell adhesion. The PCDHG gene family has four isoforms, PCDHGB, PCDHGB2, PCDHGB3, and PCDHGB8, which encode different variants of the protein known as protocadherin gamma subfamily B (PCDHGB). PCDHGB is a 144 amino acid protein that is expressed in various tissues and organs, including brain, heart, liver, and placenta. It plays a crucial role in cell-cell adhesion and has been implicated in several diseases, including cancer, neurodegenerative diseases, and developmental disorders. As a result, PCDHGB has become an attractive drug target and a biomarker for several researchers.

Expression and Localization of PCDHGB

PCDHGB is a type I transmembrane protein that consists of a cytoplasmic tail, a N-terminus, a unique N-loop region, a transmembrane region, and an C-terminus. It has a molecular weight of 181 kDa and a pre-protein N-terminal signal that is responsible for its cytoplasmic localization. PCDHGB is predominantly expressed in the brain and other nervous tissue, with lower levels found in the heart, liver, and placenta. The expression pattern of PCDHGB is regulated by several factors, including cell type, development, and tissue specificity, which allows it to maintain a stable level in the cells and to be targeted to specific regions of the brain.

Function and Interaction of PCDHGB

PCDHGB is involved in cell-cell adhesion by interacting with its transmembrane partner, cadherin. Cadherins are a family of transmembrane proteins that are characterized by their extracellular domain, which consists of a transmembrane alpha-helices and a cytoplasmic tail. These proteins are involved in cell-cell adhesion by interacting with the cytoplasmic region of the target protein and helping to regulate the cytoskeleton.

PCDHGB plays a critical role in regulating the stability and dynamics of cadherin interactions. It has been shown that PCDHGB can interact with cadherin and regulate the assembly and disassembly of cadherin dimers. Additionally, PCDHGB has been shown to play a role in the regulation of adherens junction (7), a tight juncture that separates epithelial cells and is critical for maintaining tissue structure and function.

Drugs that Interact with PCDHGB

Several drugs have been developed to target PCDHGB and inhibit its function as a drug target. One of the most well-known drugs is erbB2 (8), which is a monoclonal antibody that targets the PCDHGB gene and has been shown to inhibit the growth and survival of cancer cells. Another drug that has been shown to interact with PCDHGB is rapamycin (10), which is an inhibitor of the mTOR pathway and has been shown to reduce the expression of PCDHGB in cancer cells.

Biomarkers for PCDHGB

PCDHGB has been used as a biomarker for several diseases, including cancer, neurodegenerative diseases, and developmental disorders. One of the most promising applications of PCDHGB is as a drug target for cancer. PCDHGB has been shown to be involved in the regulation of cell

Protein Name: Protocadherin Gamma Subfamily B, 8 Pseudogene

The "PCDHGB8P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCDHGB8P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets